[IDF2011]DPP-4抑制剂维格列汀的临床应用——Marc Evans教授专访
内容概要：Dr Evans: DPP-4 inhibitors tackle one of the key pathophysiological issues of type 2 diabetes， namely islet cell dysfunction. In inhibiting the action of the enzyme DPP-4， they increase the bioavailability of